Scientific research shows that GLP-1 receptor agonist-induced weight loss produces the same fat loss characteristics in the face and buttocks as weight loss from other methods, such as a ketogenic diet.
"There's no science to show that you have a different butt when you lose weight on Ozempic versus if you lose weight by going on a ketogenic diet. You know, it's it's the same thing as far as we know." (said at 0:07:59)
No published record matching GLP-1 receptor agonist-induced facial or gluteal fat loss compared to weight loss from ketogenic diets was located; this does not prove the claim false. Clinical studies assessing body composition changes under GLP-1 receptor agonist therapy and dietary interventions focus on broad compartments—such as visceral adipose tissue, total subcutaneous fat, and lean muscle mass—rather than comparing specific gluteal or facial subcutaneous fat loss across distinct diet modalities.
- context: Adipose tissue distribution in metabolic disease: depot-specific biology, clinical assessm… (Frontiers in endocrinology 2026)
"Lifestyle intervention and glucagon-like peptide-1 receptor agonists mainly reduce visceral and ectopic fat alongside overall weight loss" (abstract, results, passage verified)
pubmedfull study (doi)